DUBLIN, Calif., May 16, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the acceptance of three abstracts for presentation at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting. Poster discussion and general poster presentations will occur on June 2 - 4 in Chicago, IL.
| Saturday, June 2, 2012 | 4:45 – 5:45 pm CT | AT13387 |
Poster Discussion
First in human Phase I study - results of a second-generation non-ansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in refractory solid tumors
| Monday, June 4, 2012 | 8:00 am – 12:00 pm CT | AT13387 |
General Poster Session
Phase I study assessing a two-consecutive-day (QD x 2) dosing schedule of the HSP90 inhibitor, AT13387, in patients with advanced solid tumors
| Sunday, June 3, 2012 | 11:30 am – 12:30 pm CT | AT9283 |
Poster Discussion
A Phase I trial of AT9283 (a selective inhibitor of Aurora kinases) given for 72 hours every 21 days via intravenous infusion in children and adolescents with relapsed and refractory solid tumors
Select posters will be made available for viewing on the company's website www.astx.com following the public presentation.
About Astex Pharmaceuticals
Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales.
For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.
The Astex Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=12273